Lilly drives more access to COVID-19 antibodies with new infusion centers

Eli Lilly's COVID-19 monoclonal antibody isn't getting as much use as it could, thanks to logistical hurdles. So the drugmaker is taking matters into its own hands.

The pharma, in partnership with local health systems, is setting up dedicated local infusion centers across its home state of Indiana, with centers already up and running in the central, northern and southern parts of the state. So far, the infusion centers have delivered antibody therapy to more than 1,700 high-risk Hoosiers with COVID-19, Lilly reported.